HIV-1 protease, reverse transcriptase, and integrase variation

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 6058-6070

  Rhee, Soo Yon ^a   Sankaran, Kris ^b   Varghese, Vici ^a   Winters, Mark A ^a,c   Hurt, Christopher B ^d   Eron, Joseph J ^d   Parkin, Neil ^e   Holmes, Susan P ^b   Holodniy, Mark ^a,c   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e DATA FIRST CONSULTING INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HYDROLASE; INTEGRASE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; SEQUENCE ANALYSIS; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMISTRY; ENZYMOLOGY; GENETIC VARIATION; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; METABOLISM; MUTATION; VIROLOGY;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; APOBEC DEAMINASES; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV INTEGRASE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84975247475     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00495-16     Document Type: Article

References (39)

1. Li G, Piampongsant S, Faria NR, Voet A, Pineda-Pena AC, Khouri R, Lemey P, Vandamme AM, Theys K. 2015. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology 12:18. http://dx.doi.org/10.1186/s12977-015-0148-6.
2. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. 2010. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84:9864-9878. http://dx.doi.org/10.1128/JVI.00915-10.
3. Onafuwa-Nuga A, Telesnitsky A. 2009. The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 73:451-480. http://dx.doi.org/10.1128/MMBR.00012-09.
4. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA, III. 1989. Complete mutagenesis of the HIV-1 protease. Nature 340:397-400. http://dx.doi.org/10.1038/340397a0.
5. Rihn SJ, Hughes J, Wilson SJ, Bieniasz PD. 2015. Uneven genetic robustness of HIV-1 integrase. J Virol 89:552-567. http://dx.doi.org/10.1128/JVI.02451-14.
6. Smith RA, Loeb LA, Preston BD. 2005. Lethal mutagenesis of HIV. Virus Res 107:215-228. http://dx.doi.org/10.1016/j.virusres.2004.11.011.
7. Keys JR, Zhou S, Anderson JA, Eron JJ, Jr, Rackoff LA, Jabara C, Swanstrom R. 2015. Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain. AIDS Res Hum Retroviruses 31: 658-668. http://dx.doi.org/10.1089/aid.2014.0031.
8. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM. 2013. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 10:18. http://dx.doi.org/10.1186/1742-4690-10-18.
9. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31:298-303. http://dx.doi.org/10.1093/nar/gkg100.
10. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, Gomez-Lopez A, Camacho RJ, de Oliveira T, Vandamme AM. 2013. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 19:337-348. http://dx.doi.org/10.1016/j.meegid.2013.04.032.
11. Learn GH, Jr, Korber BT, Foley B, Hahn BH, Wolinsky SM, Mullins JI. 1996. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol 70:5720-5730.
12. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, Fofana DB, Sayon S, Simon A, Katlama C, Calvez V, Marcelin AG. 2012. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 26:1619-1624. http://dx.doi.org/10.1097/QAD.0b013e3283560703.
13. Gifford RJ, Rhee SY, Eriksson N, Liu TF, Kiuchi M, Das AK, Shafer RW. 2008. Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS 22:717-725. http://dx.doi.org/10.1097/QAD.0b013e3282f5e07a.
14. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
15. Cornish-Bowden A. 1985. Nomenclature for incompletely specified bases in nucleic acid sequences: recommendations 1984. Nucleic Acids Res 13: 3021-3030. http://dx.doi.org/10.1093/nar/13.9.3021.
16. Holm S. 1979. A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70.
17. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmit-ted HIV-1 drug-resistance: 2009 update. PLoS One 4:e4724. http://dx.doi.org/10.1371/journal.pone.0004724.
18. Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, Towner W, Holmes SP, Zolopa AR, Shafer RW. 2009. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 53:4869-4878. http://dx.doi.org/10.1128/AAC.00592-09.
19. Ashkenazy H, Penn O, Doron-Faigenboim A, Cohen O, Cannarozzi G, Zomer O, Pupko T. 2012. FastML: a web server for probabilistic reconstruction of ancestral sequences. Nucleic Acids Res 40:W580-W584. http://dx.doi.org/10.1093/nar/gks498.
20. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 54:718-727. http://dx.doi.org/10.1128/AAC.00986-09.
21. Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 57:6223-6235. http://dx.doi.org/10.1128/AAC.01835-13.
22. Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vezinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. 2011. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 66:2827-2830. http://dx.doi.org/10.1093/jac/dkr389.
23. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2014. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med 22:642-650.
24. Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. Nat Rev Genet 5:52-61. http://dx.doi.org/10.1038/nrg1246.
25. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5:e1000414. http://dx.doi.org/10.1371/journal.ppat.1000414.
26. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489. http://dx.doi.org/10.1126/science.7824947.
27. Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG. 2013. Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. J Antimicrob Chemother 68:2199-2204. http://dx.doi.org/10.1093/jac/dkt200.
28. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W. 2000. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 74:9339-9346. http://dx.doi.org/10.1128/JVI.74.20.9339-9346.2000.
29. Huang DD, Eshleman SH, Brambilla DJ, Palumbo PE, Bremer JW. 2003. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol 41:3265-3272. http://dx.doi.org/10.1128/JCM.41.7.3265-3272.2003.
30. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR. 2012. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 50:1936-1942. http://dx.doi.org/10.1128/JCM.06689-11.
31. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. 2010. The "connection" between HIV drug resistance and RNase H. Viruses 2:1476-1503. http://dx.doi.org/10.3390/v2071476.
32. Llacer Delicado T, Torrecilla E, Holguin A. 2016. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals. J Antimicrob Chemother 71:362-366. http://dx.doi.org/10.1093/jac/dkv333.
33. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
34. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, Perrin L. 1998. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 72:3520-3523.
35. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. 2006. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80:9259-9269. http://dx.doi.org/10.1128/JVI.00888-06.
36. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. 2005. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79:1975-1980. http://dx.doi.org/10.1128/JVI.79.3.1975-1980.2005.
37. Sanchez G, Xu X, Chermann JC, Hirsch I. 1997. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 71:2233-2240.
38. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. 2009. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 14:619-629.
39. Parkin NT. 2014. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA. AIDS Rev 16:160-171.